Meanwhile, the Zofran lawsuits continue to arrive akin to a slow, but determined tide. Since February, Zofran lawsuits have begun to emerge, with Zofran manufacturer GlaxoSmithKline (GSK) submitting a petition for consolidation.
However, such legal maneuvering is lost on a mother-to-be who launched a Zofran lawsuit against GSK in April of this year after her pregnancy in the spring and summer of 2013 went horribly wrong due, or so it is alleged, to her use of Zofran.
The plaintiff, from Randolph, Massachusetts, became pregnant in May of that year and developed debilitating morning sickness, the intense nausea that many women suffer while pregnant, usually in the first trimester. Her doctor prescribed Zofran to combat the nausea.
Five months into her pregnancy, in October 2013, the plaintiff’s unborn child was diagnosed while still in the womb with “severe physical malformations, including severe and life-threatening abdominal defects,” according to her Zofran lawsuit. The malformations were of such a severe nature that the decision was made to terminate the pregnancy.
Her Zofran lawsuit, filed in US District Court for the District of Massachusetts, Eastern Division, holds Zofran and GSK directly responsible for the Zofran birth defects that doomed her unborn child. What’s more, the lawsuit alleges GSK knew about the potential for Zofran birth defects for as long as 20 years or more, but failed to disclose the risk to consumers, patients or the medical community.
READ MORE ZOFRAN BIRTH DEFECT LEGAL NEWS
GSK, in 2012, was taken to task by the US Department of Justice for allegedly promoting several drugs in its portfolio - including Zofran - off-label, which is illegal; while a doctor has the authority to prescribe drugs off-label, manufacturers are not allowed to promote or market drugs for applications beyond the original applications approved by the FDA.
The Zofran lawsuit is case number 1:15-11627, US District Court for the District of Massachusetts, Eastern Division.